COST-EFFECTIVENESS OF FIRST-LINE NIVOLUMAB COMBINATION THERAPY VS CHEMOTHERAPY ALONE FOR ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA

被引：0
|
作者：
Ben-Umeh, K. [1 ]
Okoye, G. [2 ]
Malone, D. C. [1 ]
King, J. [3 ]
机构：
[1] Univ Utah, Dept Pharmacotherapy, Coll Pharm, Salt Lake City, UT USA
[2] Univ Maryland, Sch Pharm, Baltimore, MD USA
[3] Univ Utah, Dept Populat Hlth Sci, Salt Lake City, UT USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE153
引用
收藏
页码：S87 / S88
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma
    Gong, Jinhong
    Shang, Jingjing
    Su, Dan
    Qian, Xiaodan
    Liu, Guangjun
    Sun, Zhiqiang
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (06) : 709 - 717
  • [2] Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma
    Liu, Shixian
    Dou, Lei
    Wang, Kaixuan
    Shi, Zhao
    Wang, Ruixue
    Zhu, Xiaohong
    Song, Zehua
    Li, Shunping
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma
    Rogers, Jane E.
    Yamashita, Kohei
    Sewastjanow-Silva, Matheus
    Rosa Vicentini, Ernesto
    Waters, Rebecca
    Ajani, Jaffer A.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (06) : 565 - 571
  • [4] Cost-Effectiveness Analysis of Camrelizumab vs. Placebo Added to Chemotherapy as First-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
    Zhang, Qilin
    Wu, Pan
    He, Xucheng
    Ding, Yufeng
    Shu, Yamin
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma
    Shao, Taihang
    Zhao, Mingye
    Tang, Wenxi
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
    Zhou, Chongchong
    Wei, Jingxuan
    Xu, Kai
    Lin, Yingtao
    Zhang, Lingli
    Li, Xin
    [J]. RISK MANAGEMENT AND HEALTHCARE POLICY, 2023, 16 : 2447 - 2458
  • [7] Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
    Liu, Yanhong
    Shao, Rong
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [8] Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
    Liu, Lulu
    Wang, Lei
    Chen, Li
    Ding, Yiling
    Zhang, Qilin
    Shu, Yamin
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [9] First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
    Cao, Xueqiong
    Cai, Hongfu
    Li, Na
    Zheng, Bin
    Zheng, Zhiwei
    Liu, Maobai
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [10] First-line sintilimab plus chemotherapy in locally advanced or metastatic esophageal squamous cell carcinoma: A cost-effectiveness analysis from China
    Shen, Jian
    Du, Yi
    Shao, Rong
    Jiang, Rong
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
12345